|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
21
|
|
pubmed:dateCreated |
2010-11-2
|
|
pubmed:abstractText |
Folate receptor ? expression is highly restricted in normal adult tissues but upregulated in a wide range of human cancer types, including epithelial ovarian cancer. Farletuzumab, a humanized monoclonal antibody against folate receptor ?, has shown antitumor activity and favorable toxicity in preclinical evaluation. This phase I, dose-escalation study was conducted to determine the safety of weekly i.v. farletuzumab and establish the maximum tolerated dose (MTD).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:Bell-McGuinnKatherine MKM,
pubmed-author:HensleyMartee LML,
pubmed-author:KonnerJason AJA,
pubmed-author:LarsonSteven MSM,
pubmed-author:OldLloyd JLJ,
pubmed-author:Pandit-TaskarNeetaN,
pubmed-author:PhillipsMartin DMD,
pubmed-author:SabbatiniPaulP,
pubmed-author:SchweizerCharlesC,
pubmed-author:TewWilliam PWP,
pubmed-author:Vander ElsNicholasN,
pubmed-author:WeilSusan CSC
|
|
pubmed:copyrightInfo |
©2010 AACR.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5288-95
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20855460-Adult,
pubmed-meshheading:20855460-Aged,
pubmed-meshheading:20855460-Antibodies, Monoclonal,
pubmed-meshheading:20855460-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20855460-Antineoplastic Agents,
pubmed-meshheading:20855460-Cisplatin,
pubmed-meshheading:20855460-Dose-Response Relationship, Drug,
pubmed-meshheading:20855460-Drug Resistance, Neoplasm,
pubmed-meshheading:20855460-Female,
pubmed-meshheading:20855460-Folate Receptor 1,
pubmed-meshheading:20855460-Humans,
pubmed-meshheading:20855460-Immunotherapy,
pubmed-meshheading:20855460-Middle Aged,
pubmed-meshheading:20855460-Neoplasms, Glandular and Epithelial,
pubmed-meshheading:20855460-Ovarian Neoplasms,
pubmed-meshheading:20855460-Treatment Failure,
pubmed-meshheading:20855460-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study.
|
|
pubmed:affiliation |
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA. konnerj@mskcc.org
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I,
Research Support, N.I.H., Extramural
|
